The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer.
 
Katherine Foster
Research Funding - Karyopharm Therapeutics (Inst)
 
Santosh K. Dasari
No Relationships to Disclose
 
Reid T. Powell
No Relationships to Disclose
 
Nghi D. Nguyen
No Relationships to Disclose
 
Mary Sobieski
No Relationships to Disclose
 
Clifford Stephan
No Relationships to Disclose
 
Ashwani Bahl
Employment - Carrick Therapeutics
Stock and Other Ownership Interests - Carrick Therapeutics
 
Timothy A. Yap
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - Seagen
Consulting or Advisory Role - Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Almac Group; Amphista Therapeutics; Artios; AstraZeneca; Athenahealth; Atrin Pharmaceuticals; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research UK; Circle Pharma; Clovis Oncology; Cybrexa Therapeutics; Dark Blue Therapeutics; Diffusion Pharmaceuticals; EMD Serono; F-Star; Genmab; Gerson and Lehrman Group; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; Idience; Ignyta; ImmuneSensor Therapeutics; Intellisphere; Janssen; Kyn therapeutics; MEI Pharma; Merck; Mereo BioPharma; Natera; Nexys Therapeutics; Novocure; OncoSec; Ono Pharmaceutical; Oregon Health & Science University (OHSU); Pegascy; PER; Pfizer; Piper Sandler; ProLynx; Repare Therapeutics; resTORbio; Roche; Schrodinger; Terremoto Biosciences; Theragnostics; Varian Medical Systems; Versant Health; Vibliome Therapeutics; Xinthera; Zai Lab; ZielBio
Research Funding - Acrivon Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); BMS (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Cyteir (Inst); EMD Serono (Inst); F-Star (Inst); Forbius (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Haihe Biopharma (Inst); ImmuneSensor Therapeutics (Inst); Ionis Pharmaceuticals (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); KSQ Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Tesaro (Inst); Vivace Therapeutics (Inst); Zenith Epigenetics (Inst)
 
Amir A. Jazaeri
Stock and Other Ownership Interests - Avenge Bio; Greenfire Bio
Honoraria - Gerson Lehrman Group; Guidepoint Global
Consulting or Advisory Role - Adicet Bio; Alkermes; Macrogenics; NuProbe; Theolytics
Research Funding - Aravive (Inst); AstraZeneca (Inst); Avenge Bio (Inst); Bristol-Myers Squibb (Inst); immatics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Xencor (Inst)
 
Shannon Neville Westin
Consulting or Advisory Role - AstraZeneca; Bayer; BioAscent; Caris Life Sciences; Clovis Oncology; Curio Science; Eisai; EQRX; Genentech; Gerson Lehrman Group; GlaxoSmithKline; Immunogen; Lilly; Medscape; Merck; Mereo BioPharma; Mersana; NGM Biopharmaceuticals; Nuvectis Pharma; OncLive; Roche; Seagen; Targeted Oncology; Vaniam Group; Vincerx Pharma; Zentalis
Research Funding - AstraZeneca (Inst); Avenge Bio (Inst); Bayer (Inst); Bio-Path Holdings, Inc (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Mereo BioPharma (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Roche/Genentech (Inst); Zentalis (Inst)
 
Anil K Sood
Stock and Other Ownership Interests - Bio-Path Holdings, Inc
Consulting or Advisory Role - GlaxoSmithKline; ImmunoGen; Iylon; KIYATEC; Merck; Onxeo
Patents, Royalties, Other Intellectual Property - EGFL6 antibodies